Navigation Links
New drug treatment extends lives of men with prostate cancer
Date:5/26/2011

AURORA, Colo. (May 25, 2011) - A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months. The study in the May 26, 2011 issue of the New England Journal of Medicine was co-authored by Thomas W. Flaig, MD, medical oncologist at the University of Colorado Hospital's Tony Grampsas Urologic Oncology Clinic and assistant professor at the University of Colorado School of Medicine.

"Abiraterone acetate is a new, life-extending pill for the treatment of advanced prostate cancer. Unlike the traditional chemotherapy drugs used in these situations, abiraterone is generally very well tolerated," said Flaig.

The multi-center Phase III clinical trial of 1195 participants looked at the effectiveness of treating patients who had received prior chemotherapy with a combination of abiraterone acetate (ZytigaTM ) and prednisone. When this trial was initiated, there were no treatments that clearly prolonged survival in this late phase of prostate cancer. The patients were randomized to receive abiraterone acetate plus prednisone or a placebo plus prednisone each day. Treatment continued until the cancer progressed, there were unfavorable reactions, a new treatment was initiated or the patient withdrew from the trial.

The study shows participants taking abiraterone acetate lived about four months longer than participants taking the placebo. In addition, more patients receiving abiraterone acetate experienced a significant drop in the PSA blood level than those on the placebo.

"The survival benefit observed in this study is especially notable, since this was seen in the most advanced cases of prostate cancer," said Flaig. "Other studies are being done to examine the benefit of using abiraterone acetate earlier in the disease process, whe
'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
720-848-7852
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Unique nerve-stimulation treatment proves effective against drug-resistant epilepsy
2. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
3. US study shows that tofacitinib is an efficacious treatment for active RA
4. Research suggests that lipofilling may be safe during conservation treatment for breast cancer
5. New study aims to improve long-term treatment for patients with bipolar disorder
6. PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients
7. IUPUI study first to look at early treatment of depression to reduce heart disease risk
8. Mount Sinai researchers discover possible new target for sarcoma treatment and prevention
9. Quicker detection and treatment of severe sepsis
10. Substantial recovery rate with placebo effect in headache treatment
11. Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 2015 , ... According to a study published August 25th in ... in a three year study about weight loss and diabetes were far more likely ... loss surgery at the onset of the trial. In fact, the participants in the ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted ... ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn ... some of whom work for Calvary, and two junior counselors who were campers themselves ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the American Society for Dermatologic Surgery, according to a new survey that ... Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
... 18 (HealthDay News) -- Flu vaccination levels among U.S. ... are still below the 2020 national health objectives, a ... for Disease Control and Prevention also found that too ... care personnel should get an annual flu vaccination, according ...
... tumors aren,t uniform: they are more like complex societies, ... playing different roles. Understanding this "social structure" of tumors ... different cell types may be sensitive to different drugs. ... society, in which all cancer cells descend from special ...
... Fighting Drug, Vemurafenib Powerful X-Rays Enable ... Life-Threatening Diseases WASHINGTON, DC Powerful X-ray ... (DOE,s) national laboratories is revealing new insights into ... and, most recently, enabled the discovery of a ...
... , THURSDAY, Aug. 18 (HealthDay News) -- Many doctors continue ... guidelines say some women can wait much longer between tests. ... Katherine Roland, a behavioral scientist at the U.S. Centers for ... with the guidelines," Roland said. The downsides of too-frequent ...
... For the first time, researchers at Seattle Cancer ... serial positron emission tomography (PET) scans, using a ... of estrogen-blocking and estrogen-depleting therapy in patients with ... are published online in Clinical Cancer Research ...
... , WEDNESDAY, Aug. 17 (HealthDay News) -- A newer ... consciousness while under anesthesia is no better than conventional ... new research shows. In fact, the newer system ... is known as bispectral index (BIS) monitoring -- actually ...
Cached Medicine News:Health News:Flu Shot Rates Low for Health Workers, Moms-to-Be: CDC 2Health News:Cancer stem cells made, not born 2Health News:Cancer stem cells made, not born 3Health News:DOE laboratories help develop promising new cancer fighting drug, vemurafenib 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 3Health News:PET scans confirm effectiveness of estrogen-blocking drugs in breast cancer patients 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 3
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
(Date:9/1/2015)... RIVER, Mass. , Sept. 1, 2015   ... an additional 120,000 square feet in Olive Branch, ... Olive Branch facility has added the ... warehousing space. "This expansion gives us the ... Karl Neuberger , President of Millstone MS. "Two and a ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2
... NEW YORK, Jan. 12, 2011 InstaCare Corp. ... prescription and non-prescription diagnostics, home testing products for ... direct to patient diabetes programs, and a leading ... technologies, today announced that the company,s Board of ...
... 2011 At the 29th Annual J.P. Morgan Healthcare Conference, ... that based on a preliminary review of 2010 results, it ... more than $3.5 billion compared to 2009. Adjusted cash earnings ... the midpoint of the company,s latest forecast of $3.37 to ...
Cached Medicine Technology:InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA 2Watson Announces Preliminary Financial Performance for FY 2010 2Watson Announces Preliminary Financial Performance for FY 2010 3Watson Announces Preliminary Financial Performance for FY 2010 4
... HT is designed for extended temperatures. ... ideal for applications such as DNA ... Incubator/Shaker HT is available as a ... three microplates. Iems Incubator/Shaker HT including ...
... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer for any kind of cell ... CyFlow SL analyzes forward and side ... to 3 fluorescence channels. Data acquisition, ... with a PC or laptop employing ...
Medicine Products: